MOLECULAR ANALYSIS OF THE CAMP- RESPONSE ELEMENT [CRE] ELEMENTS IN THE PROMOTER REGION AND EXON 1 OF THE SURVIVAL OF MOTOR NEURON 2 [SMN2] GENE IN MALAYSIAN SPINAL MUSCULAR ATROPHY PATIENTS; TO ELUCIDATE THEIR ROLE IN CIRCUMSCRIBING THE CLINICAL SEVERITY
Keywords:
SMA, CRE-II, CREB, Promoter of SMN geneAbstract
Objective: In the Spinal muscular atrophy [SMA] genes [SMN1 and SMN2 genes]; the CRE-II elements at -400 bp in the promoter region of the SMN genes and CRE-I element at +108 bp in the exon 1 of the SMN genes, are reported to have a role in c-AMP induce expression of the SMN genes through its binding affinity to CREB-1. This study was designed to determine the role of CRE sites in the circumscribing the clinical severity of SMA.
Methods: Direct sequencing was performed for the PCR products of the promoter regions of the SMA patients with homozygous deletion of SMN1, different copy number of SMN2 and NAIP non deletion.
Results: No variation among the CRE-I and CRE-II sites was found in all the clinical types as compare to normal healthy control showing no role of CRE sites in circumscribing the clinical severity of SMA.
Conclusion: There was no sequence variation found in the CRE binding sites in the three different clinical types of SMA reflecting no role of CRE binding sites in circumscribing the clinical severity of SMA.
Downloads
References
Myriam Vezain, Pascale Saugier-Veber, Judith Melki, Annick Toutain, Eric Bieth, Marie Husson, et al. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Eur J Hum Genet 2007:15:1054–62.
Sarmila Majumder, Saradhadevi Varadharaj, Kalpana Ghoshal, Umrao Monani, Arthur HM Burghes. Identification of a Novel Cyclic AMP-response Element [CRE-II] and the Role of CREB-1 in the cAMP-induced Expression of the Survival Motor Neuron [SMN] Gene. J Biol Chem 2004:279(15):14803–11.
Boda B, Mas C, Giudicelli C, Zvara A, Santha M, LeGall I, et al. Direct Submission of sequence, Submitted Neurogenetique, INSERM E9935, Hopital Robert Debre 48 bvd Serurier, Paris 75019, France; 1999.
Zerres K, Davies KE. 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria, The Netherlands. Neuromuscul Disord 1999:9:272–8.
Zerres K, Rudnik Scho¨neborn S. [Naarden, The Netherlands]. 93rd ENMC International Workshop: non-5q-spinal muscular atrophies [SMA]–clinical picture. Neuromuscul Disord April 2001:13:179–83.
Zielenski J, Bozon D, Kerem B, Markiewicz D, Durie P, Rommens JM, et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator [CFTR] gene. Genomics 1991:10:229–35.
Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002:70:358–68.
Watihayati MS, Fatemeh H, Marini M, Atif AB, Zahiruddin WM, Sasongko TH, et al. Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy. Brain Dev 2009:31:42–5.
Eva Zapletalova, Petra Hedvicakova, Libor Kozak, Petr Vondracek, Renata Gaillyova, Tatana Marikova, et al. Analysis of point mutations in the SMN1 gene in SMA patients bearing a single SMN1 copy. J Neuromuscular Disorder 2007:17:476-81.
Talbot K, Ponting CP, Theodosiou AM, Rodrigues N, Surtees R, Mountford R, et al. Missense mutation clustering in the survival motor neuron gene: a role for a conserved Tyrosine and Glysine rich region of the protein and RNA metabolism? Hum Mol Genet 1997:6:497-500.
Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001:10:2841-9.
Baron-Delage S, Abadie A, Echaniz LA, Melki J, Beretta L. Interferons and IRF-1 induce expression of the survival motor neuron [SMN] genes. Mol Med 2000:6:957-68.
Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001:98:9808–13.
Hai T, Liu F, Coukos WJ, Green MR. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 1989:3:2083–90.
Monani UR, McPherson JD, Burghes AHM. Promoter analysis of the human centromeric and telomeric survival motor neuron genes [SMNC and SMNT]. Biochim Biophys Acta 1999:1445;330–6.
Sumner CJ. Therapeutics development for spinal muscular atrophy. Neuro Rx, 2006:3:235–45.
Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genetics Med 2002:4[1]:20-5.
Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997:16:265–9